Home>Topics>Stocks>Vical Incorporated

Vical Incorporated VICL

  1. All
  2. Commentary
    1. Dropping Coverage of Vical


      Mon, 3 Aug 2009

      We are no longer providing equity research on Vical VICL . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.

    2. Good Data for Vical's H1N1 Vaccine


      Tue, 30 Jun 2009

      Vical VICL has reported positive preclinical results from its H1N1 swine flu vaccine, but we will maintain our fair value estimate until

    3. Vical Plans to Develop H1N1 Vaccine


      Thu, 7 May 2009

      Vical VICL announced strong first-quarter results and a collaboration with the U.S. Navy on swine flu, or H1N1 influenza, Thursday

    4. Vical's Pipeline On Track


      Fri, 20 Feb 2009

      We are maintaining our fair value estimate for Vical VICL as its development progress remains on track. The firm burned through $7 million in cash during the fourth quarter and ended

    5. Vical Announces Restructuring


      Fri, 21 Nov 2008

      On Friday, Vical VICL announced plans to restructure its operations. While this will reduce its near-term cash burn, we are holding firm to our fair

    6. Lowering Vical's Uncertainty Rating


      Wed, 22 Oct 2008

      After running more valuation scenarios, we're returning our fair value uncertainty rating for Vical VICL to very high from extreme. Our fair value estimate remains unchanged. Our current valuation depends on Vical obtaining about

    7. Raising Vical's Uncertainty Rating


      Mon, 6 Oct 2008

      We're raising our fair value uncertainty rating for Vical VICL to extreme from very high to account for the stock market's recent volatility. Until we have a better sense of the firm's

    8. Vical under Review


      Mon, 29 Sep 2008

      We are putting Vical VICL under review. We will reassess our fair value uncertainty rating for the firm given its need to pursue dilutive activities at potentially unattractive prices. We will publish a new report shortly.

    9. Vical under Review


      Wed, 17 Sep 2008

      We're placing Vical VICL under review, as we think its declining share price could hamper its ability to raise capital at fair levels. The firm may have

    10. Vical's Vaccine Shows Promise


      Thu, 17 Jul 2008

      Vical VICL announced promising results for its Phase I DNA vaccine for pandemic flu recently that could result in a new alternative to conventional

    « Prev12Next »
    Content Partners